Skin Cancer Home > Zelboraf and Breastfeeding
The manufacturer of Zelboraf (vemurafenib) recommends that women not take this drug while breastfeeding, as Zelboraf is associated with potentially dangerous problems. However, no research has been done to determine if this drug passes through breast milk. If your healthcare provider recommends this drug while nursing, be watchful for possible problems in your child, such as excessive crying, vomiting, or diarrhea.
Can Breastfeeding Women Take Zelboraf?Zelboraf™ (vemurafenib) is a prescription medication used in the treatment of a type of skin cancer known as melanoma. Melanoma is less common than other types of skin cancer, but is more likely to spread (metastasize) in the body. Zelboraf is used when the cancer has spread or cannot be treated with surgery.
It is unknown whether this medication passes through breast milk in humans. The manufacturer recommends that women not breastfeed while taking Zelboraf.
More Information About Zelboraf and BreastfeedingZelboraf has not been studied in breastfeeding women. Therefore, it is unknown whether the medication passes through breast milk, or whether it would harm a nursing child.
The manufacturer of Zelboraf recommends the drug not be used in women who are breastfeeding. This is because Zelboraf is associated with potentially serious side effects, including serious skin reactions, heart rhythm problems, and liver problems. Due to the lack of information on breastfeeding while taking Zelboraf, the risk for these and other side effects in a nursing infant cannot be ruled out.
If, however, your healthcare provider recommends taking this drug while you are breastfeeding, be sure to watch for any problems in your child, and contact your child's healthcare provider if you notice anything out of the ordinary. Possible problems may include but are not limited to:
- Excessive crying
- Extreme sleepiness
- Rash, skin redness, or other skin changes
- Difficulty feeding